🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 102 of 151

  1. Placebo for LAD603, LAD603

    Almirall, S.A.

    Alopecia areata

    phase 2 small molecule active

    1 trial

  2. Placebo for MK-7240, tulisokibart

    Merck Sharp and Dohme

    Radiographic axial spondyloarthritis (as known as ankylosing spondylitis)

    phase 2 small molecule active

    1 trial

  3. Placebo for ML-007C-MA bilayer tablet

    MapLight Therapeutics

    Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

    phase 2 small molecule active

    1 trial

  4. Placebo for MRM-3379, MRM-3379, MRM-3379

    Lacuna Pharma Pty Ltd

    ​​Fragile X Syndrome​

    phase 2 small molecule active

    1 trial

  5. Placebo for SPT-300

    Seaport Therapeutics

    Major Depressive Disorder (MDD), with or without Anxious Distress

    phase 2 small molecule active

    1 trial

  6. Placebo for TransCon CNP, TransCon CNP 3.9 mg CNP-38/vial, Navepegritide 2.8 mg CNP(89-126), Navepegritide 1.3 mg CNP(89-126)

    Lacuna Pharma Pty Ltd

    Achondroplasia in Children and Adolescents

    phase 2 small molecule active

    1 trial

  7. Placebo for bms-986435-01

    Bristol-Myers Squibb Australia Pty Ltd

    Heart failure with preserved ejection fraction (HFpEF)

    phase 2 small molecule active

    1 trial

  8. Placebo for petrelintide, Petrelintide, Petrelintide

    Zealand Pharma A/S

    Weight management

    phase 2 small molecule active

    1 trial

  9. Placebo for pf-07328948 tablet (CCI) mg, Placebo for pf-07328948 tablet (CCI) mg

    Pfizer Australia Pty Ltd

    Heart failure

    phase 2 small molecule active

    1 trial

  10. Placebo for ponsegromab (PF-06946860) solution for injection, Ponsegromab (PF-06946860)

    Pfizer Australia Pty Ltd

    Cancer cachexia

    phase 2 small molecule active

    1 trial

  11. Placebo is identical with the test product and just does not contain active substance.

    Lacuna Pharma Pty Ltd

    Prurigo Nodularis

    phase 2 small molecule active

    1 trial

  12. Placebo matching BI 764198, BI 764198

    Boehringer Ingelheim

    Proteinuric kidney diseases

    phase 2 small molecule active

    1 trial

  13. Placebo matching BLU-808, tablet, BLU-808, BLU-808

    Blueprint Medicines (Netherlands) B.V.

    Chronic Inducible Urticaria and Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  14. Placebo matching REGN9933, REGN7508, REGN9933, Placebo matching REGN7508

    Lacuna Pharma Pty Ltd

    Venous Thromboembolism

    phase 2 small molecule active

    1 trial

  15. Placebo matching with ZED1227 capsules of Dr. Falk Pharma GmbH, CEC02, CEC03

    Dr. Falk Pharma GmbH

    Celiac Disease

    phase 2 small molecule active

    1 trial

  16. Placebo of Dexamfetamine sulfate 20 mg modified-release capsule, Dexamfetamine sulfate 20 mg modified-release capsule, Attentin 5 mg, Tablette, Dexamfetamine sulfate 15 mg modified-release capsule, Dexamfetamine sulfate 10 mg modified-release capsule, Placebo of Attentin 5 mg 10 mg tablets, Placebo of Dexamfetamine sulfate 15 mg modified-release capsule, Attentin 10 mg Tablette, Placebo of Dexamfetamine sulfate 10 mg modified-release capsule

    Lacuna Pharma Pty Ltd

    Adults with ADHD and moderate to severe depression

    phase 2 small molecule active

    1 trial

  17. Placebo of IPN10200, IPN10200

    Ipsen

    Cervical Dystonia

    phase 2 small molecule active

    1 trial

  18. Placebo of NAL, NACYSTELYN

    Laboratoire HRA Pharma

    Obstructive Sleep Apnea

    phase 2 small molecule active

    1 trial

  19. Placebo of leflunomide, Arava 20 mg film-coated tablets, Mycophenolate mofetil Teva 500 mg film-coated tablets, Placebo of mycophenolate mofetil, Placebo of hydroxychloroquine, PLAQUENIL 200 mg, comprimé pelliculé

    Pari Pharma GmbH

    Primary Sjogren's syndrome

    phase 2 small molecule active

    1 trial

  20. Placebo oral capsule

    United Therapeutics Europe Ltd

    Osteoarthritis, Knee

    phase 2 small molecule completed

    1 trial

  21. Placebo session 1, Aprepitant session 2

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  22. Placebo solution for injection matching COR-1167, COR-1167

    Lacuna Pharma Pty Ltd

    Worsening Heart Failure

    phase 2 small molecule active

    1 trial

  23. Placebo sterile solution for SC injection, Obexelimab

    Zenas BioPharma

    RELAPSING MULTIPLE SCLEROSIS

    phase 2 small molecule active

    1 trial

  24. Placebo tablets are produced with the same appearance as the Valganciclovir tablets, with the same content except for the active compound., VALGANCICLOVIR

    The George Institute

    Glioblstoma WHO grade IV

    phase 2 small molecule active

    1 trial

  25. Placebo to ARGX-117 IV concentrate solution for infusion, ARGX-117

    argenx

    Myositis, Dermatomyositis

    phase 2 small molecule active

    1 trial

  26. Placebo to ARGX-117 IV, ARGX-117, ARGX-117

    argenx

    Multifocal Motor Neuropathy

    phase 2 small molecule active

    1 trial

  27. Placebo to ARGX-119 concentrate for solution for infusion, ARGX-119

    argenx

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  28. Placebo to AVTX-009, AVTX-009

    Avalo Therapeutics

    Hidradenitis suppurativa (HS)

    phase 2 small molecule active

    1 trial

  29. Placebo to BAY 3401016, BAY 3401016

    Bayer AG

    Alport Syndrome, Chronic kidney disease

    phase 2 small molecule active

    1 trial

  30. Placebo to BI 765423, BI 765423

    Boehringer Ingelheim

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  31. Placebo to BYL719 50 mg film-coated tablets (Light Yellow) Placebo to BYL719 125 mg film-coated tablets (Dark Yellow), BYL719, BYL719, BYL719, BYL719, BYL719

    Novartis Pharmaceuticals

    PIK3CA-Related Overgrowth Spectrum (PROS)

    phase 2 small molecule active

    1 trial

  32. Placebo to Basimglurant (Microcrystalline Cellulose Spheres (Vivapur 1000) and hard Gelatin Capsule, Opaque white body/Opaque white cap, Size 1), Basimglurant, Basimglurant

    Lacuna Pharma Pty Ltd

    Tuberous Sclerosis Complex

    phase 2 small molecule active

    1 trial

  33. Placebo to ISL, Placebo to MK-8507, Placebo to BIC/FTC/TAF, EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR, islatravir, ulonivirine

    Merck Sharp and Dohme

    HIV-1 Infection

    phase 2 small molecule active

    1 trial

  34. Placebo to LTP001 00mg hard gelatin capsule, LTP001, LTP001, Placebo to LTP001 00mg hard gelatin capsule

    Novartis Pharmaceuticals

    Part A: Healthy volunteers (Part A is not applicable to the EU; for information only) Part B: pulmonary arterial hypertension

    phase 2 small molecule active

    1 trial

  35. Placebo to MAS825 100 mg/1 mL Concentrate for solution for infusion / Solution for injection, -, CICLOSPORIN , MAS825

    Novartis Pharmaceuticals

    Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis), X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency, or Cell division control protein 42 homolog (CDC42) mutation.

    phase 2 small molecule active

    1 trial

  36. Placebo to MK-1167, MK-1167, MK-1167, MK-1167

    Merck Sharp and Dohme

    Alzheimer’s disease dementia

    phase 2 small molecule active

    1 trial

  37. Placebo to MK-6194, MK-6194

    Merck Sharp and Dohme

    Non segmental vitiligo

    phase 2 small molecule active

    1 trial

  38. Placebo to Match GSK3915393 Tablet

    GlaxoSmithKline

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  39. Placebo to Match GSK3965193 Tablets

    GlaxoSmithKline

    Hepatitis B

    phase 2 small molecule active

    1 trial

  40. Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device, TQJ230

    Novartis Pharmaceuticals

    Calcific Aortic Valve Stenosis

    phase 2 small molecule active

    1 trial

  41. Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion, mRNA-4157

    Merck Sharp and Dohme

    Melanoma

    phase 2 small molecule active

    1 trial

  42. Placebo to match 5-mg PTC518 tablets, Placebo to match 20-mg PTC518 tablets, PTC518, PTC518

    PTC THERAPEUTICS, INC.

    Huntington’s Disease

    phase 2 small molecule active

    1 trial

  43. Placebo to match ACP-204

    Lacuna Pharma Pty Ltd

    Alzheimer Disease psychosis

    phase 2 small molecule active

    1 trial

  44. Placebo to match ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680

    Alkermes Pharma Ireland

    Narcolepsy Type 1

    phase 2 small molecule active

    1 trial

  45. Placebo to match ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680

    Alkermes Pharma Ireland

    Narcolepsy Type 2

    phase 2 small molecule active

    1 trial

  46. Placebo to match DNTH103, Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, DNTH103, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, c

    Dianthus Therapeutics, Inc. /DE/

    Generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  47. Placebo to match IMP Lu AG09222

    H. Lundbeck A/S

    Migraine

    phase 2 small molecule active

    1 trial

  48. Placebo to match IMP TEV-56286, Emrusolmin

    Lacuna Pharma Pty Ltd

    Multiple System Atrophy

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.